跳转至内容
Merck
CN

Y0000475

Carboprost trometamol

European Pharmacopoeia (EP) Reference Standard

别名:

(5Z,9α,11α,13E,15S)-9,11,15-Trihydroxy-15- methylprosta-5,13-dien-1-oic acid with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), Carboprost tromethamine

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C25H47NO8
化学文摘社编号:
分子量:
489.64
UNSPSC Code:
41116107
NACRES:
NA.24
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

NC(CO)(CO)CO.O[C@H]1[C@H](C([C@H](C1)O)\C=C/[C@@](O)(CCCCC)C)C\C=C\CCCC(=O)O

InChI

1S/C21H36O5.C4H11NO3/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25;5-4(1-6,2-7)3-8/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25);6-8H,1-3,5H2/b7-5+,14-12-;/t16-,17?,18+,19-,21-;/m0./s1

InChI key

UMMADZJLZAPZAW-QFXCEMDRSA-N

grade

pharmaceutical primary standard

API family

carboprost

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Carboprost trometamol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

法规信息

监管及禁止进口产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

L A Levine et al.
Cancer, 66(2), 242-245 (1990-07-15)
The treatment of cyclophosphamide-induced hemorrhagic cystitis has been difficult, with overall poor results using intensive and costly therapy. The authors evaluated the treatment of this problem in four patients with prostaglandin intravesical therapy. Each patient had failed to respond to
L A Levine et al.
The Journal of urology, 149(4), 719-723 (1993-04-01)
We review our experience with 18 consecutive patients who received intravesical carboprost tromethamine, an F2-alpha prostaglandin, for severe hemorrhagic cystitis following cyclophosphamide chemotherapy. Of the patients 16 were given cyclophosphamide for conditioning before bone marrow transplantation and 2 received the
Combined bladder and uterine rupture following prostaglandin-induced midtrimester abortion: an unreported event.
Umber Agarwal et al.
Acta obstetricia et gynecologica Scandinavica, 82(10), 974-975 (2003-09-06)
R F Lamont et al.
Prostaglandins & other lipid mediators, 66(3), 203-210 (2001-10-02)
In a prospective, open-label, assessor-blind, randomised parallel group study the efficacy and safety of Hemabate (Pharmacia-Upjohn Pharmaceuticals, Milton Keynes, Buckinghamshire) an analogue of 15-methyl-prostaglandin (PGF2alpha) analogue was compared with Syntometrine (Alliance Pharmaceuticals, Chippenham, Wilts) the standard combination of ergometrine and
D M Kranc et al.
The Journal of urology, 148(4), 1326-1330 (1992-10-01)
Recently, prostaglandins have been shown to be effective agents for the treatment of cyclophosphamide-induced hemorrhagic cystitis. Among the prostaglandins studied is carboprost tromethamine, a PGF2a analog. To determine the effectiveness of carboprost tromethamine therapy on the urothelium, we induced hemorrhagic

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持